Physician profile
Benjamin D Liba
NPI 1801389333
$2,021.94
in general payments reported to CMS, 2019-2025
11 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $160 · 2023: $505 · 2024: $916 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690 · Travel and Lodging: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.35 |
| Travel and Lodging | $171.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $798.46 | 2023-2025 | Inspire |
| Genzyme Corporation | $349.83 | 2023-2025 | |
| Glaxosmithkline, LLC. | $180.78 | 2023-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $163.58 | 2023-2025 | Dupixent |
| Medical Device Business Services, INC. | $159.99 | 2020 | |
| Aerin Medical INC. | $150.35 | 2025 | |
| Medtronic, INC. | $66.94 | 2024 | Propel |
| Optinose US, INC. | $55.10 | 2024-2025 | |
| Smith+Nephew, INC. | $41.36 | 2025 | Halo, Tula |
| Merck Sharp & Dohme LLC | $33.34 | 2023 | |
| Alk-Abello, INC | $22.21 | 2025 | Grastek, Ragwitek, Odactra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Liba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.